Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.

Publications show all

Alethia Biotherapeutics has published 1 articles.

Patents show all

76Applications51Issued

Clinical Trials show all

1Phase 1